Democrats in the House of Representatives will introduce a bill today that seeks to reaffirm the authority of the FDA on drug approvals, after a Texas court held that the
Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment availab